Sol-Gel Clinical Trial Information

We are pleased to share updated information on the Sol-Gel clinical trial that is now recruiting participants for the topical medication to prevent the development of basal cell carcinomas in those over 18 years of age with Gorlin syndrome.

A) Below are the cities / states where Sol-Gel is in the process of activating sites. Currently, we are not able to provide detailed contact information.  There is no guarantee that these locations will be activated as contracts are still being negotiated.

  • Redwood City, California
  • Los Angeles, California
  • New Haven, Connecticut
  • Baltimore, Maryland
  • Boston, Massachusetts
  • Ann Arbor, Michigan
  • Durham, North Carolina
  • Cleveland, Ohio
  • Portland, Oregon
  • Hershey, Pennsylvania
  • Lake Geneva, Wisconsin

B) The following clinical trial sites listed below are currently open and actively recruiting.

NORTHEAST

Coming Soon

SOUTHEAST

  • Dr. Cheryl Hull
    Northwest Arkansas Clinical Trials Center, PLLC
    599 S. Horsebarn Rd.
    Suite 200
    Rogers, AR 72758Briana Tedford, B.S.
    Clinical Research Coordinator
    Northwest Arkansas Clinical Trials Center, PLLC
    599 S. Horsebarn Rd.
    Suite 200
    Rogers, AR 72758
    Phone: (479) 876-8205 Ext. 4
    Fax : (479) 876-8049

SOUTHWEST

  • Dr. Timothy Rodgers
    North Texas Center for Clinical Research
    3880 Parkwood Blvd Suite 102
    Frisco, TX 75034Keisha Neal
    Chief Operating Officer
    (214) 618-0220
    (214) 783-5185

MIDWEST

  • Dr. Steven Kempers
    Minnesota Clinical Study Center
    119 14th St NW Suite 250
    New Brighton, MN 55112 USA
    PI: Steven Kempers
    Contact Business Phone Number: 763-571-4200Jenjira Skrei, BA, CCRC
    Research Manager
    Minnesota Clinical Study Center
    119 14th Street NW, Suite 250
    New Brighton, MN 55112
    office: 763-571-4200
    fax: 763-502-2975
  • Dr. Jorge Garcia-Zuazaga
    Apex Clinical Research Center
    29111 Cedar Road
    Mayfield Heights, OH 44124Brooke Glivar, LPN, CCRC |Research Site Manager
    Apex Clinical Research Center, LLCApex Skin Corporate Office
    29111 Cedar Road
    Mayfield Heights, OH 44124
    Cell: 330-933-2180
    Office: 440-940-APEX

WEST

  • Dr. Sunil Dhawan
    Center for Dermatology Clinical Research, Inc.
    2557 Mowry Ave Suite 34
    Fremont, CA, USA 94538
  • Leanne Saud MA
    Clinical Research Coordinator
    Center for Dermatology, Clinical Research, Inc.
    2557 Mowry Ave, Ste 34
    Fremont, CA 94538
    Phone: 510-797-0140×5
  • Dom Mitchell
    Pronouns: she|her|hers
    Clinical Research Coordinator
    Stanford University School of Medicine – Department of Dermatology
    Stanford Skin Innovation and Interventional Research Group (SIIRG)
    455 Broadway St. Discovery Hall 1st Fl., Redwood City, CA 94063, MC 8843
    email: domcm@stanford.edu | phone: (650) 721-7192 | fax: (650) 498-5908

C) Information on inclusion and exclusion criterion can be found:

  1. On the GSA’s website by clicking here.
  2. At clinicaltrials.gov

D) Sol-Gel has set up a phone number to call with further questions.

This is: (833) 958-0014

Questions about Gorlin syndrome that are not related to this clinical trial should be directed to info@gorlinsyndrome.org or call 267-689-6443

Further information on this trial will be provided as soon as it is available.

Please consider becoming a hero to the Gorlin syndrome community by participating in this clinical trial.

Dear Gorlin Syndrome Alliance Community,

Please allow us to introduce to you an opportunity to enroll in a clinical study to find out how well Patidegib Gel 2% works in preventing new basal cell carcinomas (BCCs) developing on the face of adults with Gorlin syndrome, and how safe Patidegib Gel 2% is to use. If you meet the criteria for this study, you will be expected to apply the medication to your face twice a day for one year (12 months). This is a double-blind study which means that neither you or the clinical investigator at the trial site will know if you are applying the drug or a placebo. The number of new BCCs that develop will be monitored in all participants.

Patidegib Gel 2% was investigated in a clinical study in the past and while not meeting FDA success criteria, it was clearly proven that it reduced the total number of new facial BCC by 40% compared to placebo in those with the PTCH1 mutation and with a high burden of BCCs.

The study is sponsored by Sol-Gel Technologies, an innovative dermatology pharmaceutical company known for pioneering topical drugs focused on both common and rare skin conditions such as in this case Gorlin Syndrome. Sol-Gel has contracted Premier Research, a top global clinical research organization (CRO) dedicated to helping transform lifechanging ideas and breakthrough science into new medical treatments in the pharmaceutical industry.

In our efforts to meet the needs of your community whose mission is to support, educate and seek the best treatments for those living with Gorlin Syndrome, Premier Research has set up a dedicated Patient Referral Service staffed by our Patient Support Team to refer potential patients to participating sites throughout the United States of America. The toll-free number is +1 (833) 958-0014 and the hours of operation are 8:00am EST to 5pm EST, Monday thru Friday. Callers will be provided with a list of sites to contact that have opted into this referral service. No pre-screening will be conducted and in order to maintain and respect your privacy, no personal information will be collected when you call this service. All study-specific requirements or questions will be addressed by the clinical trial site of the potential patients’ choice.

We are delighted for this opportunity to partner and collaborate with you as individuals, and a community as a whole, with the goal of improving the lives of those who are impacted and their loved ones, in further clinical research by developing an innovative treatment option for Gorlin Syndrome.

Kind Regards,

Your Sol-Gel/Premier Research Study Team

For information on all clinical trials, go to clinicaltrials.gov.